Christophe Bardin

ORCID: 0000-0003-2826-6129
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pharmaceutical Practices and Patient Outcomes
  • French Urban and Social Studies
  • Cultural Insights and Digital Impacts
  • Pharmaceutical studies and practices
  • Diabetes Treatment and Management
  • Safe Handling of Antineoplastic Drugs
  • Historical Studies and Socio-cultural Analysis
  • French Historical and Cultural Studies
  • Metabolism, Diabetes, and Cancer
  • Cultural Identity and Heritage
  • Pharmacy and Medical Practices
  • Chronic Myeloid Leukemia Treatments
  • Statistical Methods in Clinical Trials
  • Pain Mechanisms and Treatments
  • Autoimmune and Inflammatory Disorders Research
  • HIV/AIDS drug development and treatment
  • Pain Management and Opioid Use
  • HIV Research and Treatment
  • Herpesvirus Infections and Treatments
  • Hyperglycemia and glycemic control in critically ill and hospitalized patients
  • Antibiotics Pharmacokinetics and Efficacy
  • Epilepsy research and treatment
  • Lung Cancer Treatments and Mutations
  • HER2/EGFR in Cancer Research
  • Ocular Surface and Contact Lens

Université Paris Cité
2013-2025

Hôpital Cochin
2012-2025

Assistance Publique – Hôpitaux de Paris
2008-2024

Société Française de Cardiologie
2023

Centre de Recherche des Cordeliers
2021

Sorbonne Université
2021

Inserm
1996-2021

Centre de Recherche Saint-Antoine
2021

Centre de Gestion Scientifique
2021

Centre National de la Recherche Scientifique
2021

<h3>Objectives</h3> To assess the efficacy of interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA). <h3>Methods</h3> A multicentre, randomised, double-blind, placebo-controlled trial was conducted. The primary objective to compare a 1-month treatment with (2 mg/kg subcutaneous daily, maximum 100 mg) placebo between two groups each 12 patients SJIA. Response defined by 30% improvement paediatric American College Rheumatology criteria for JIA,...

10.1136/ard.2010.134254 article EN Annals of the Rheumatic Diseases 2010-12-20

Mifepristone and a prostaglandin have been used successfully to terminate pregnancy in Europe China. We report the results of large U.S. study mifepristone misoprostol women with pregnancies up nine weeks' duration.

10.1056/nejm199804303381801 article EN New England Journal of Medicine 1998-04-30

The present study shows no adverse effects of the anti-diabetic drug metformin on bone mass and fracture healing in rodents but demonstrates that is not osteogenic vivo, as previously proposed. In view increased incidence fractures patients with type 2 diabetes mellitus (T2DM), we investigated metformin, a widely used T2DM therapy, vivo using two different rodent models modes administration. We first subjected 12-week-old female C57BL/6 mice to ovariectomy (OVX). Four weeks after OVX,...

10.1007/s00198-013-2371-0 article EN cc-by-nc Osteoporosis International 2013-05-03

Anakinra pharmacokinetics and pharmacodynamics were investigated in children adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) autoinflammatory syndromes.Anakinra was given subcutaneously at doses between 2 10 mg/kg (maximum 100 mg) per day. concentrations recorded patients, as well C-reactive protein (CRP) levels, on different occasions. The data fitted to a pharmacokinetic-pharmacodynamic model via population approach using Monolix.A total of 87 adolescents, 8...

10.1186/2050-6511-14-40 article EN cc-by BMC Pharmacology and Toxicology 2013-08-05

To determine the maximum-tolerated dose (MTD), dose-limiting toxicities and pharmacokinetic of semisynthetic homoharringtonine (ssHHT), given as a twice daily subcutaneous (s.c.) injections for 9 days, in patients with advanced acute leukaemia, 18 myeloid leukaemia were included this sequential Bayesian phase I dose-finding trial. A starting 0.5 mg m−2 day−1 was explored subsequent escalations 1, 3, 5 6 day−1. Myelosuppression constant. The MTD estimated level consecutive days by s.c. route....

10.1038/sj.bjc.6603265 article EN cc-by-nc-sa British Journal of Cancer 2006-07-18

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and one of leading causes cancer-related deaths worldwide. The multitarget inhibitor sorafenib a first-line treatment patients with advanced unresectable HCC. Recent clinical studies have evidenced that treated together antidiabetic drug metformin survival disadvantage compared receiving only. Here, we examined whether clinically relevant dose (50 mg/kg per day) could influence antitumoral effects (15 in subcutaneous...

10.1124/molpharm.120.000223 article EN Molecular Pharmacology 2021-05-14

Abstract Introduction Methadone, the most widely delivered maintenance therapy for heroin addicts, may be responsible life-threatening poisonings with respiratory depression. The toxicokinetics and toxicokinetic/toxicodynamic (TK/TD) relationships of methadone enantiomers have been poorly investigated in acute poisonings. aim this study was to describe between methadone-related effects their corresponding concentrations. Methods We report a 44-year-old methadone-maintained patient who...

10.1186/cc5150 article EN cc-by Critical Care 2007-01-15

Plasma concentration of ganciclovir was studied prospectively in 15 AIDS patients treated for acute cytomegalovirus (CMV) retinitis. Ganciclovir administered at a mean dose 10.3 +/- 0.6 mg/kg/day. The trough plasma 0.3 mg/L (n = 24), and the peak 7.2 2.4 6). In 12 patients, concentrations were below range that has been associated with effective treatment. Low treatment failure 6 patients. Following an increase daily dose, improvement observed 4 These results suggest low levels are therapy....

10.1093/infdis/174.1.188 article EN The Journal of Infectious Diseases 1996-07-01

Abstract Introduction: The European Society of Oncology Pharmacy (ESOP) Global has almost 4000 members across 70 countries. Over the past few decades, focus oncology pharmacists shifted, from a mostly product-based role to include patient-centric care model, often termed clinical pharmacy. To map advancement integration pharmacy into daily practice, survey was conducted among ESOP in 2023. Methods: A comprising 28 questions distributed full membership. Questions were grouped obtain...

10.1097/op9.0000000000000055 article EN European Journal of Oncology Pharmacy 2024-04-01
Coming Soon ...